

CLAIMS

We claim:

1. A method of inhibiting thrombotic conditions in blood in a subject in need thereof comprising administering to the subject an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.
2. The method of claim 1, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.
3. A kit for inhibiting thrombotic conditions in blood comprising an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.
4. A method for treating or preventing a thrombotic condition in blood in a subject in need thereof comprising administering to the subject an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.
5. The method of claim 4, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.
6. A kit for treating or preventing a thrombotic condition in blood comprising an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.

7. A method for inhibiting formation of blood platelet aggregates in blood comprising adding to blood a therapeutically effective amount of an inhibitor of *syk* kinase.
8. A kit for inhibiting formation of blood platelet aggregates in blood comprising an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.
9. A method of identifying a compound useful in the treatment of a thrombotic condition, comprising screening a library of candidate compounds to identify those compounds which sustain constitutive eNOS activity during platelet aggregation.
10. A method of treating a thrombotic condition in a subject in need thereof comprising administering to the subject the compound identified by claim 9.
11. The method of claim 10, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.
12. The method of claim 11, wherein the treatment of a thrombotic condition is selected from the group consisting of inhibiting a thrombotic condition, treating a thrombotic condition, and preventing a thrombotic condition.
13. A kit for treating a thrombotic condition comprising the compound of claim 9 and a pharmaceutically acceptable carrier.

14. A method of identifying a compound useful in the treatment of a thrombotic condition, comprising screening a library of candidate compounds to identify those compounds which inhibit calpain and sustain constitutive eNOS activity during platelet aggregation.

15. A method of treating a thrombotic condition in a subject in need thereof comprising administering to the subject the compound identified by claim 14.

16. The method of claim 15, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.

17. The method of claim 15, wherein the treatment of a thrombotic condition is selected from the group consisting of inhibiting a thrombotic condition, treating a thrombotic condition, and preventing a thrombotic condition.

18. A kit for treating a thrombotic condition comprising the compound of claim 14 and a pharmaceutically acceptable carrier.

19. A method of identifying a compound useful in the treatment of thrombosis, comprising screening a library of candidate compounds to identify those compounds which inhibit GPIIb/IIIa and sustain constitutive eNOS activity during platelet aggregation.

20. A method of treating a thrombotic condition in a subject in need thereof comprising administering to the subject the compound identified by claim 19.

21. The method of claim 20, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.

22. The method of claim 20, wherein the treatment of a thrombotic condition is selected from the group consisting of inhibiting a thrombotic condition, treating a thrombotic condition, and preventing a thrombotic condition.

23. A kit for treating a thrombotic condition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

24. A method of promoting fibrinolysis in a subject in need thereof comprising administering to the subject a compound selected from the group consisting of an inhibitor of *syk* kinase and an inhibitor of calpain, and a pharmaceutically acceptable carrier.

25. The method of claim 24 wherein the compound is an inhibitor of *syk* kinase.

26. The method of claim 24 wherein the compound is an inhibitor of calpain.

27. A kit for promoting fibrinolysis comprising the compound of claim 24 and a pharmaceutically acceptable carrier.